A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia

Inclusion Criteria

• •All patients 1 year and less than 10 years of age.
• •Patient must be diagnosed with acute lymphoblastic leukemia.
• •All CCG patients must be enrolled on CCG 1952, 1962 or 1991 protocols, or be treated according to a CCG standard risk ALL protocol. NCI patients must be treated according to CCG 1952 for the treatment of standard risk ALL. Enrollment onto the current trial (CCG B9802) should if possible take place concurrently with enrollment onto 1952/1962/1991 or start of treatment according to a CCG standard risk ALL protocol.
• •All patients or their legal guardians must sign a document of informed consent indicating their awareness of the investigational nature and the risks of this study.